fam-trastuzumab deruxtecan-nxki (Enhertu) Report issue

Biologics mAb ADC Approved FDA Fast Track FDA Accelerated Approval FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Trastuzumab deruxtecan, sold under the brand name Enhertu, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to the topoisomerase I inhibitor deruxtecan. It is licensed for the treatment of breast cancer or gastric or gastroesophageal adenocarcinoma. Trastuzumab binds to and blocks signaling through epidermal growth factor receptor 2 (HER2/neu) on cancers that rely on it for growth. Additionally, once bound to HER2 receptors, the antibody is internalized by the cell, carrying the bound deruxtecan along with it, where it interferes with the cell's ability to make DNA structural changes and replicate its DNA during cell division, leading to DNA damage when the cell attempts to replicate itself, destroying the cell.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Payload: deruxtecan
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Drug Pricing (per unit)

United States

$1734.3400 - $2261.3600
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

ds-8201a | rg-1512

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue